| Assessment Status | Rapid Review Complete |
| HTA ID | 25020 |
| Drug | Belzutifan |
| Brand | Welireg® |
| Indication | Belzutifan is indicated for the treatment of adult patients with von Hippel-Lindau disease who require therapy for associated, localised renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for whom localised procedures are unsuitable. |
| Assessment Process | |
| Rapid review commissioned | 06/03/2025 |
| Rapid review completed | 31/03/2025 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of belzutifan compared with the current standard of care. |
